Some data have revealed that cancer cells can escape immune surveillance by overexpressing TDO2 and activating AhR in a range of cells of both the innate and adaptive immune system—dendritic cells, macrophages, natural killer cells, innate lymphoid cells, cytotoxic T cells and regulatory T cells (32, 33). This evidence concerns the gene AHR and cancer.